drugset / Trial / NCT00241085
Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a study of whether valsartan affects levels of proteinuria in patients with type 2 diabetes and hypertension.
Timeline
- Start
- 2002-11
- Primary completion
- 2005-08
- Completion
- 2005-08
Publications
- Natale P, Palmer SC, Navaneethan SD, Craig JC, Strippoli GF. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2024 Apr 29;4(4):CD006257. doi: 10.1002/14651858.CD006257.pub2.
- Weir MR, Hollenberg NK, Zappe DH, Meng X, Parving HH, Viberti G, Remuzzi G. Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. J Hypertens. 2010 Jan;28(1):186-93. doi: 10.1097/HJH.0b013e328332bd61.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valsartan | Small molecule | 160 mg | — |
| Subject | Valsartan | Small molecule | 320 mg | — |
| Subject | Valsartan | Small molecule | 640 mg | — |